2016年8月
Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer
CANCER GENE THERAPY
- 巻
- 23
- 号
- 8
- 開始ページ
- 278
- 終了ページ
- 283
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1038/cgt.2016.31
- 出版者・発行元
- NATURE PUBLISHING GROUP
Reduced expression in immortalized cells (REIC)/dickkopf-3 (Dkk-3), a tumor suppressor gene, is downregulated in various cancers. We previously reported the tumor-inhibitory effects of the REIC/Dkk-3 gene, delivered by a conventional adenoviral vector (Ad-CAG-REIC) in pancreatic cancer. Here, we developed an Ad-REIC vector with a novel gene expression system, termed the super gene expression (SGE) system, and assessed its therapeutic effects relative to those of Ad-CAG-REIC in pantreatic cancer cells. Human pancreatic cancer cell lines ASPC1 and MIAPaCa2 were used. REIC/Dkk-3 expression was assessed by western blot analysis. Relative cell viability and apoptotic effects were examined in vitro. The anti-tumor effects of Ad-REIC treatment were assessed in the mouse xenograft model. Compared with Ad-CAG-REIC, Ad-SGE-REIC elicited a significant increase in REIC protein expression in the cells studied, Relative to Ad-CAG-REIC, Ad-SGE-REIC reduced cell viability and induced apoptosis in the ASPC1 and MIAPaCa2 cell lines in vitro, and achieved superior tumor growth inhibition in the mouse xenograft model. Compared with conventional Ad-REIC agents, Ad-SGE-REIC provided enhanced inhibitory effects against tumor growth. Our results indicate that Ad-SGE-REIC is an innovative therapeutic tool for pancreatic cancer.
- リンク情報
- ID情報
-
- DOI : 10.1038/cgt.2016.31
- ISSN : 0929-1903
- eISSN : 1476-5500
- Web of Science ID : WOS:000381658500006